(Q35179548)

7 August 2017

1 reference

title

Gabapentin dosing in the treatment of epilepsy (English)

1 reference

7 August 2017

0 references

Michael J McLean

1

1 reference

7 August 2017

Barry E Gidal

series ordinal

2

1 reference

7 August 2017

publication date

1 May 2003

1 reference

7 August 2017

published in

Clinical Therapeutics

1 reference

7 August 2017

volume

25

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

1382-1406

1 reference

Psychosocial well-being and epilepsy: an empirical study

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Commission on Outcome Measurement in Epilepsy, 1994-1997: final report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Seizure frequency and the health-related quality of life of adults with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Relationships between seizure severity and health-related quality of life in refractory localization-related epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

The cost of epilepsy in the United States: an estimate from population-based clinical and survey data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Fortnightly review: drug treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Newer anticonvulsants: comparative review of drug interactions and adverse effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

1 reference

7 January 2021

Safety review of adult clinical trial experience with lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Adverse reactions to new anticonvulsant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

An audit of topiramate use in a general neurology clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Levetiracetam: a different approach to the pharmacotherapy of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Behavioural effects of the new anticonvulsants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Rapid initiation of gabapentin: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Dosing to efficacy with neurontin: the STEPS trial. Study of Titration to Effect Profile of Safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Pharmacokinetics of gabapentin in subjects with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Single-dose gabapentin pharmacokinetics and safety in healthy infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Oral gabapentin disposition in patients with epilepsy after a high-protein meal.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin absorption: effect of mixing with foods of varying macronutrient composition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

1 reference

7 January 2021

Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Effect of a high-protein meal on gabapentin pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Lack of serious toxicity following gabapentin overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

A case of sustained massive gabapentin overdose without serious side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Long-term treatment with gabapentin for partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Lamotrigine-associated rash: risk/benefit considerations in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Topiramate titration and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin in the management of convulsive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Cognitive abilities and adjustment with gabapentin: results of a multisite study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Weight gain and gabapentin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Changes in body weight with chronic, high-dose gabapentin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Behavioral side effects of gabapentin in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin associated with aggressive behavior in pediatric patients with seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

Efficacy and tolerance of long-term, high-dose gabapentin: additional observations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980127-3

7 January 2021

10.1016/S0149-2918(03)80127-3

Identifiers

DOI

1 reference

7 August 2017

1 reference